AETHLON MEDICAL, INC. (NASDAQ:AEMD) Files An 8-K Other EventsITEM 8.01 Other Events
On October 4, 2017, Aethlon Medical, Inc. (the “Company’) closed its previously announced public offering of 5,454,546 shares of common stock and warrants to purchase 5,454,546 shares of common stock, for total gross proceeds of$6.0 million. The offering was priced at$1.10per unit with each unit comprised of one share of common stock and one common stock purchase warrant. The warrants carry a five-year term with an exercise price of$1.10per share.
H.C. Wainwright& Co. acted as exclusive placement agent for the offering.
The securities were offered to a registration statement on Form S-1 (File No. 333-219589) previously filed with the Securities and Exchange Commission (the "SEC") and declared effective onSeptember 29, 2017. The securities may be offered only by means of a prospectus. The final prospectus related to the offering has been filed with the SEC. Copies of the final prospectus may be obtained at the SEC's website located athttp://www.sec.gov, and may also be obtained fromH.C. Wainwright& Co., LLC by calling (646) 975-6996 or [email protected].
This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
After consummation of this offering, the Company has 15,073,455 shares of its common stock issued and outstanding.
About AETHLON MEDICAL, INC. (NASDAQ:AEMD)
Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.
